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Resistance to widely used fungistatic drugs, particularly to the ergosterol biosynthesis inhibitor
fluconazole, threatens millions of immunocompromised patients susceptible to invasive fungal
infections. The dense network structure of synthetic lethal genetic interactions in yeast suggests
that combinatorial network inhibitionmay afford increased drug efficacy and specificity.We carried
out systematic screens with a bioactive library enriched for off-patent drugs to identify compounds
that potentiate fluconazole action in pathogenic Candida and Cryptococcus strains and the model
yeast Saccharomyces. Many compounds exhibited species- or genus-specific synergism, and often
improved fluconazole from fungistatic to fungicidal activity. Mode of action studies revealed two
classes of synergistic compound, which either perturbed membrane permeability or inhibited
sphingolipid biosynthesis. Synergistic drug interactions were rationalized by global genetic
interaction networks and, notably, higher order drug combinations further potentiated the activity
of fluconazole. Synergistic combinations were active against fluconazole-resistant clinical isolates
and an in vivo model of Cryptococcus infection. The systematic repurposing of approved drugs
against a spectrum of pathogens thus identifies network vulnerabilities that may be exploited to
increase the activity and repertoire of antifungal agents.
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Introduction
The recent increase in fungal infection rates presents a serious
clinical challenge (Arendrup et al, 2009; Gullo, 2009; Shorr et al,
2009). Immune-suppressed individuals, including transplant,
cancer chemotherapy and HIV-infected patients, often succumb
to opportunistic fungal pathogens from the genera Candida,
Cryptococcus, Aspergillus and others (Groll et al, 1996; Baddley
et al, 2001; Clark and Hajjeh, 2002; Richardson and Warnock,
2003). Unlike bacterial infections that can be treated with
multiple antibiotic classes, therapeutic options for fungal
infections are limited. The polyene amphotericin B, discovered
in 1955, remains a front line fungicidal drug; however,
amphotericin Bnon-specifically disrupts cellmembrane integrity,
with concomitant severe patient toxicity. Synthetic azole
antifungals such as fluconazole were introduced 40 years ago
and inhibit lanosterol 14a-demethylase, the gene product of
ERG11, an essential cytochrome P450 enzyme in the ergosterol
biosynthetic pathway (Groll et al, 1998; Revankar et al, 2004).
Fluconazole binds to the heme Fe(III) of Erg11, resulting in
depletion of ergosterol, the accumulation of C-14 methyl sterols
and cell membrane disruption. The crossreactivity of azoles
toward human P450 enzymes also results in toxicity and,
moreover, clinical resistance is prevalent (Cannon et al, 2009;
Marie and White, 2009). Finally, the echinocandins, which
include caspofungin, micafungin and anidulafungin, were
introduced 10 years ago and inhibit the cell wall biosynthesis
enzyme b-(1,3)-D-glucan synthase; however, these agents have a
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restricted antifungal spectrum (Sucher et al, 2009). The dearth of
selective agents and emerging patterns of clinical resistance
demand new antifungal strategies.
A primary challenge in antifungal drug discovery is the
paucity of fungal-specific molecular targets that are essential
for cell growth, due to the conserved biochemical and
molecular biological networks of all eukaryotes. This problem
is exacerbated by the observation that many essential yeast
genes can provide sufficient function at a fraction of wild-type
dosage (Yan et al, 2009). Although onlyB1100 of the B6000
genes in yeast are essential under nutrient-rich growth
conditions (Winzeler et al, 1999), almost all genes become
essential in specific genetic backgrounds in which another
non-essential gene has been deleted or otherwise attenuated,
an effect termed synthetic lethality (Tong et al, 2001). Genome-
scale surveys suggest that over 200 000 binary synthetic lethal
gene combinations dominate the yeast genetic landscape
(Costanzo et al, 2010). The genetic buffering phenomenon is
also manifest as a phalanx of differential chemical–genetic
interactions in the presence of sublethal doses of bioactive
compounds (Hillenmeyer et al, 2008). These observations
illuminate the inherent redundancy of genetic networks, and
frame the problem of interdicting network functions with
single agent therapeutics (Hopkins, 2008).
This genetic network organization suggests that judicious
combinations of small molecule inhibitors of both essential
and non-essential targets may elicit additive or synergistic
effects on cell growth (Sharom et al, 2004; Agoston et al, 2005;
Fitzgerald et al, 2006; Lehar et al, 2007, 2008; Hopkins, 2008).
Indeed, ad hoc combinations of anti-infective drugs are
frequently used to treat fungal infections (Eliopoulos and
Moellering, 1991; Johnson and Perfect, 2010). However, this
chance approach fails to exploit richness of the chemical–
genetic landscape (Sharom et al, 2004; Hopkins, 2008;
Lehar et al, 2008). Instead, unbiased screens for synergistic
enhancers of a specific bioactivity that are not themselves
active, sometimes termed syncretic combinations, are needed
to fully explore chemical space (Keith et al, 2005). Compounds
that enhance the activity of known agents in model yeast and
cancer cell line systems have been identified both by focused
small molecule library screens (Borisy et al, 2003; Zhang et al,
2007; Zhai et al, 2010) and by computational methods (Lehar
et al, 2007; Nelander et al, 2008; Jansen et al, 2009; Zinner
et al, 2009). Furthermore, direct tests of synergistic com-
pounds have successfully yielded combinations that are active
against pathogenic fungi, including the combination of
fluconazole with chemical inhibitors of Hsp90, calcineurin or
ARF (Cowen et al, 2009; Singh et al, 2009; Epp et al, 2010) and
the antibiotic polymyxin B (Zhai et al, 2010).
To extend the strategy of chemical synthetic lethality to
clinically relevant fungal pathogens, we interrogated a focused
bioactive library of known drugs for synergistic enhancers of
the fungistatic drug fluconazole in systematic screens against
Candida albicans, Cryptococcus neoformans and Cryptococcus
gattii, as well as the genetically tractable budding yeast
Saccharomyces cerevisiae. Compounds not previously recognized
in the clinic as antifungal agents caused potent growth inhibition
in conjunction with fluconazole, often in a genus- or species-
specific manner. Selected combinations were characterized for
mechanismof action and shown to be active against fluconazole-
resistant isolates and efficacious in an in vivo infection model.
The combinatorial redeployment of known drugs defines a
powerful antifungal strategy and establishes a number of
potential lead combinations for future clinical assessment.
Results
Systematic antifungal potentiation screens
in model and pathogenic fungi
Cell-based high-throughput screens were performed on a
panel of four fungal strains to identify small molecules that
potentiate fluconazole across a range of genera and species.
The human pathogens C. neoformans (H99), C. gattii (R265)
and C. albicans (Caf2-1) as well as the model fungus S.
cerevisiae (BY4741) were screened in duplicate against the
Prestwick library, which consists of 1120 off-patent drugs and
other bioactive agents (http://www.prestwickchemical.com).
To identify compounds that potentiate the effect of flucona-
zole, yet have minimal antifungal activity on their own, each
screen was performed in the presence and absence of 0.5
minimal inhibitory concentration (MIC) of fluconazole at a
single compound concentration of 30mM. Residual activity
was calculated for each compound and all data were normal-
ized for plate- and row/column-specific effects (Supplemen-
tary Figure S1; see Supplementary Table S1 for screen data).
Hits were determined using median absolute deviation (MAD)
statistics. By this criterion, 43 compounds were active against
S. cerevisiae, 30 against C. albicans, 70 against C. neoformans
and 91 against C. gattii (Figure 1A and B).
The set of 148 compounds that potentiated the antifungal
action of fluconazole in one or more of the screens
(Supplementary Figure S2) was structurally diverse and
represented a broad range of different therapeutic activities,
including antiparasitics, cardiovascular protectives, dermato-
logicals, genitourinary tract anti-infectives, hormone modula-
tors and a variety of neuroleptic drugs. Notably, 15 of the 17
tricyclic phenothiazine/thioxanthene antipsychotics present
in the Prestwick library exhibited strong interactions with
fluconazole against C. gattii and C. neoformans (Figure 1C).
Derivatives of tricyclic phenothiazines inhibit fatty acid
synthesis and disrupt lipid trafficking (Li et al, 2008).
A striking number of hits were species or genus specific
(Figure 1B). Six compounds were hits in all screens: (i)
the antidepressant sertraline (Zolofts); (ii) the monoamine
oxygenase inhibitor pirlindole, also known to have antide-
pressant activity; (iii) the allylamine antifungal naftifine; (iv)
the antibiotic prodrug pivampicillin; (v) the antinausea drug
thiethylperazine (Torecans); and (vi) the antipsychotic drug
zuclopenthixol. The latter two compounds are members of the
large family of phenothiazines that have antipsychotic and
other central nervous system (CNS) activities.
Synergy assessment and fungicidal activity
To determine whether hit compounds acted in a synergistic
or additive manner with fluconazole, we selected 12 of the
148 hits (albendazole, azaperone, clofazimine, clomiphene,
L-cycloserine, kawain, lynestrenol, mitoxantrone, sertraline,
suloctidil, tamoxifen and trifluoperazine) for detailed studies
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in all four fungal species. We based this selection on an
analysis of distinct chemical class, with one or two represen-
tative structures from families of similar agents that emerged
in the screen, commercial availability of compound, thera-
peutic importance, and knownmode of action (Supplementary
Figure S3). These criteria yielded a tractable number of hit
compounds for detailed downstream analysis. We also tested
five known antifungal drugs, both as positive controls and to
explore other potential interactions with fluconazole: ampho-
tericin B, the ergosterol biosynthesis inhibitors ketoconazole,
terbinafine (an allylamine analog of naftifine used in the
clinic) and fenpropidin (an agricultural fungicide), and the
echinocandin caspofungin. Dose-dependent MIC values for
these 17 compounds were determined for each of the four
species (Supplementary Table S2). The interaction of each
compound with fluconazole was assessed by standard con-
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Figure 1 Unbiased screens for bioactive compounds that potentiate the antifungal activity of fluconazole. (A) Scatter plots for Prestwick library screens for four fungal
species. Growth inhibition caused by compounds in the absence (x axis) and presence of fluconazole (y axis) is represented by residual activity after treatment. Yellow
and red filled circles indicate compounds that were classified as active (2 median absolute deviations below the diagonal). Compounds that inhibited growth in the
presence of fluconazole by at least 80% compared with the effect of that compound alone are highlighted in red; FLC, fluconazole. (B) Overlap of hits between different
fungal species. (C) Activity of 17 phenothiazine/thioxathene compounds in different fungal species.
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centration matrix (checkerboard) analysis (Figure 2A; Supple-
mentary Table S3). Data were quantified by calculation of the
fractional inhibitory concentration index (FICI), the accepted
method for drug interactions in infectious disease (Eliopoulos
and Moellering, 1991; Odds, 2003). Only two compounds,
sertraline and trifluoperazine, exhibited synergy with fluco-
nazole against all four fungal species. A number of synergizers
exerted effects exclusively on a particular species: S. cerevisiae
was uniquely susceptible to four different compounds in
the presence of fluconazole (clofazimine, clomiphene,
L-cycloserine and mitoxantrone), while only C. albicans was
susceptible to ketoconazole or caspofungin in combination
with fluconazole. Neither Cryptococcus species exhibited any
unique synergistic susceptibilities. Most hits from the screens
were confirmed as synergistic with fluconazole, except for
albendazole, azoperone and kawain in S. cerevisiae, and
azaperone, L-cycloserine and lynestrenol in C. albicans
(Supplementary Figure S4). Quantification of interactions at
different drug concentrations revealed some additional syner-
gies with fluconazole: trifluoperazine exhibited synergy
against C. albicans, tamoxifen against C. gattii and C. neofor-
mans, and suloctidil against C. neoformans and S. cerevisiae
(Supplementary Figure S4). Based on the detailed analysis of
these 12 compounds, the high-throughput screens proved a
reliable means to identify synergistic drug interactions, with
an estimated false positive rate of 0.20 and a false negative rate
of 0.28. Importantly, and in contrast to the merely fungistatic
effect of fluconazole alone, several combinations of flucona-
zole and different synergistic compounds were fungicidal,
often in a species-dependentmanner (Figure 2A). For example,
trifluoperazine exhibited synergy with fluconazole and was
fungicidal in all species with the exception of C. albicans.
Chemical–genetic profiles of synergistic
combinations
We explored the molecular basis for the synergy of trifluoperazine,
tamoxifen, clomiphene, sertraline, suloctidil and L-cycloserine with
fluconazole (Figure 2B), using established genome-wide methods
in S. cerevisiae to identify gene deletion strains that are sensitive to
drug treatment (Giaever et al, 1999;Parsons et al, 2006;Hillenmeyer
et al, 2008). Genome-wide pools of deletion strains were grown in
the presence of drugs, genomicDNA isolated fromdrug-treated and
control cultures, and barcode sequence tags amplified and
hybridized to barcode microarrays (Cook et al, 2008).
First, we profiled compound action in haplo-insufficiency
screens, in which the B1000 deletion strains heterozygous for
essential genes were tested for drug sensitivity to identify
candidate drug targets (Giaever et al, 1999). As expected,
deletion of one copy of ERG11 conferred sensitivity to fluconazole
(Figure 3A; Supplementary Figure S5). Deletion of one copy of
either LCB1 or LCB2, which encode subunits of the enzyme
serine palmitoyltransferase that catalyzes the committed step of
sphingolipid biosynthesis, caused sensitivity to L-cycloserine
(Figure 3A; Supplementary Figure S5). In yeast membrane
extracts, high concentrations of L-cycloserine (1mM) partially
inhibit serine palmitoyltransferase (Pinto et al, 1992). All five
remaining compounds—trifluoperazine, tamoxifen, clomiphene,
sertraline and suloctidil (referred to as the membrane active
group)—conferred sensitivity to loss of one copy of the NEO1
gene (Figure 3A; Supplementary Figure S5), which encodes an
essential aminophospholipid translocase required for membrane
trafficking and vacuolar biogenesis. Deletion of the ortholog of
NEO1 inC. neoformans (APT1) has recently been shown to result
in hypersensitivity to amphotericin B and fluconazole, as well as
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attenuated virulence (Hu and Kronstad, 2010). In addition,
deletion of one copy of TIM54, a translocase of the inner
mitochondrial membrane, confers sensitivity to tamoxifen and
trifluoperazine (Figure 3A), consistent with the potential
membrane targets of these drugs.
We then generated haploid chemical–genetic profiles for the
syncretic compounds individually and in combination with
fluconazole (Supplementary Figure S6). This profiling method
reveals genes that buffer against drug toxicity and can identify
compounds with similar bioactivities based on shared chemical–
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genetic interaction profiles (Hillenmeyer et al, 2008). Strains
deleted for genes that function in vesicle-mediated transport and
membrane organization were sensitive to fluconazole alone
(Figure 3B). For drug combinations, we chose a concentration of
fluconazole (6mg/ml) that caused B20% growth inhibition
compared with control and thereby minimized the selection
against fluconazole-sensitive strains. Importantly, the syncretic
drugs alone did not impair the growth of fluconazole-sensitive
deletion strains (Figure 3B; Supplementary Figure S5), but
significantly sensitized cells to low doses of fluconazole
(Supplementary Table S4). To explore the potential mechanism
of this sensitization further, we examined the chemical–genetic
profiles of single compounds (Figure 3C; Supplementary Figure
S7; Supplementary Table S5). The membrane active group of
trifluoperazine, tamoxifen, clomiphene, sertraline and suloctidil
caused growth inhibition of a core set of deletion strains that
included genes that encode the post-Golgi-associated aminopho-
spholipid translocase (flippase) Drs2 and its activating subunit
Cdc50, the ergosterol biosynthesis enzyme Erg6, the protein
trafficking factors Sac1 and Vps74, the mitochondrial outer
membrane import factors Mdm10 and Mdm12, and the cell wall
integrity MAPK kinase Slt2 and its upstream activating kinase
Bck1. A number of genes implicated in downstream steps of
sphingolipid metabolism, including IPT1, SUR1, SKN1, YPK1
and SWH1, were also required for cell survival in the presence of
the membrane active compounds. Notably, strains disrupted
for non-essential genes implicated in uncoating of clathrin
vesicles (SWA2) and retrograde transport to the cis-Golgi net-
work (YPT6, RGP1, RIC1 and VPS52) were resistant to all six
fluconazole synergizers, suggesting that altered vesicle traffick-
ing may compensate for membrane perturbation and/or Erg11
inhibition.
We confirmed the chemical–genetic interactions between
these haploid deletion strains and each drug using quanti-
tative growth curve assays (Figure 3D). We also assessed
strains that were heterozygous for ERG11, NEO1, LCB1
and LCB2 as well as TIM18 and TIM22, which function in a
complex with TIM54. In addition, we included haploid
deletion strains for DNF1/2/3, the other three flippases in
S. cerevisiae, and LCB3/4/5, which function downstream
of LCB1/2. The quantitative growth curves corroborated
the barcode microarray results, with the exception of the
dubious ORF YOR072W. The range of drug concentrations
tested in the growth curve assays revealed additional
chemical–genetic interactions, such as TIM18, which were
not recovered at the single drug concentrations used in the
barcode profiles.
The results of these genome-wide chemical–genetic screens
point to two related modes of action for the syncretic
combinations tested. Trifluoperazine, tamoxifen, clomiphene,
sertraline and suloctidil appear to cause general perturbation
of membrane, vesicle trafficking and lipid biosynthesis
functions, whereas L-cycloserine preferentially interferes with
an early step in sphingolipid biosynthesis, consistent with its
proposed mechanism of action (Pinto et al, 1992). To test the
latter hypothesis, we examined the effects ofmyriocin, another
known inhibitor of the first step of the sphingolipid biosynth-
esis pathway (Miyake et al, 1995), and found that it also
potentiated the inhibition of cell growth by fluconazole
(FICI¼0.625).
Cell biological effects of synergistic combinations
We assessed the effects of trifluoperazine, tamoxifen, sertra-
line and L-cycloserine alone and in combination with
fluconazole on S. cerevisiae cell physiology. The diagnostic
fluorescent dyes Calcofluor White, FM4-64 and Mitotracker
Green were used to visualize cell wall and bud scars, vacuolar
membranes and mitochondria, respectively. For each reporter
dye, fluconazole produced staining patterns that were similar
to solvent controls. In contrast, treatment with trifluoperazine,
tamoxifen, clomiphene and sertraline caused a drastic loss
of localization and strong intracellular accumulation of each
dye (Figure 4A; Supplementary Figure S8). In particular, the
disruption of vacuolar structure revealed by FM4-64 staining
suggested severe loss of cell membrane integrity. Consistent
with its different genetic target profile, treatment with L-
cycloserine had no observable effects on the localization of
any of the dyes (Figure 4B).
Lethal perturbation of themembrane and/or cellwall can often
be rescued by osmotic stabilization. Sorbitol (1M) effectively
suppressed the syncretic growth inhibitory effects of trifluoper-
azine, tamoxifen, clomiphene, sertraline and suloctidil, again
supporting a common membrane perturbation mechanism for
these compounds, but had no such protective effect on cells
treatedwith L-cycloserine andfluconazole (Figure 4C). These cell
biological results affirm the differentmechanisms of action of the
two compound classes.
Integration of chemical–gene interactions with
genetic interaction networks
A primary challenge in the discovery of synergistic drug
combinations is the vast number of possible combinations of
drug pairs (Sharom et al, 2004; Hopkins, 2008; Lehar et al,
2008). Integration of drug-induced gene expression profiles
(Lum et al, 2004) and chemical–genetic profiles (Hillenmeyer
et al, 2008) with comprehensive genetic interaction networks
(Costanzo et al, 2010) can allow computational prediction of
synergistic drug pairs (Lehar et al, 2007; Nelander et al, 2008;
Jansen et al, 2009). To assess whether the individual profiles of
fluconazole and each of the syncretic drugs could rationalize
drug interactions, we integrated the chemical–genetic profiles
generated above for each syncretic compound with a global
genetic interaction network composed of both high-through-
put (HTP) and low-throughput (LTP) data compiled from the
primary literature (Breitkreutz et al, 2008; Costanzo et al,
2010). Deletion strains that were sensitive to treatment with
single drugs were used to assess the number of genetic
interactions linked to the chemical–genetic space (CGS) of
fluconazole and each of the synergizers. A core set of haploid
deletion strains affected by the membrane active group of
compounds, referred to as the signature strain set (Figure 3D),
exhibited many genetic interactions with the top 50 flucona-
zole-sensitive strains (Figure 5A). The top 50 most sensitive
deletion strains for each individual drug (Z-scores above
B2.0) also showed many genetic interactions with the
fluconazole profile. We tested the significance of the genetic
connections between the profiles using simulations of genetic
interactions shared between randomly chosen gene sets of a
specific size, based on the known chemical sensitivities of 1143
Syncretic antifungal compound combinations
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Figure 4 Effects of syncretic drugs on membrane integrity. A wild-type S. cerevisiae strain was grown in the presence of the indicated drugs and stained with
(i) Calcofluor White M2R, (ii) FM4-64 and (iii) Mitotracker Green FM, and imaged by fluorescence microscopy. (A) Sertraline (128 mg/ml) in the presence and absence
of fluconazole (64 mg/ml). (B) L-Cycloserine (128 mg/ml) in the presence and absence of fluconazole (128 mg/ml). (C) Growth of wild-type S. cerevisiae compared
with control wells in the presence of the indicated drugs with and without 1 M sorbitol. The mean of four independent measurements is shown; error bars represent
standard error. Source data is available for this figure at www.nature.com/msb.
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non-essential deletion strains that respond to various drug
treatments (Hillenmeyer et al, 2008). The signature deletion
set shared by the membrane active group was significantly
enriched for genetic interactions with fluconazole-sensitive
deletion strains (P-value o107). The individual profiles for
tamoxifen, trifluoperazine, clomiphene, sertraline and suloc-
tidil also showed a significant enrichment of genetic inter-
actions with the fluconazole-sensitive strain profile (all
P-values o0.05), whereas L-cycloserine did not (Figure 5B;
Supplementary Table S6). As a more conservative measure
of pathway separation (Kelley and Ideker, 2005), we applied
a parallel pathway permutation (PPP) test, in which the
chemical–genetic interactors of fluconazole and each of the
synergistic drugs were pooled and randomly assigned to two
groups (Supplementary Figure S9). By this stringent method,
the signature deletion set and the top 50 most sensitive
deletion strains from the trifluoperazine profile also exhibited
significant enrichment (both P-values o0.05; Supplementary
Figure S9; Supplementary Table S6). The genetic interactions
that link the chemogenomic profiles of synergistic compound
pairs thus provide a rational basis for synergism.
To assess the predictive power of the signature deletion
set derived from the membrane active compounds, we
retrospectively analyzed chemical–genetic profiles for 81
psychoactive drugs known to impair yeast growth (Ericson
et al, 2008). Of this set, 16 compounds were represented in the
Prestwick library, 7 of which were predicted to synergize with
fluconazole based on their effect on deletion strains in the
signature set. In our primary screens against the four fungal
species, four of these seven compoundswere indeed hits in our
screen, while the other three compounds showed weak
activity (Figure 5C; Supplementary Table S1). These results
demonstrate that chemical–genetic interaction profiles can
predict synergistic drug combinations.
Species-specific effects of ergosterol pathway
inhibition
As the psychiatric drugs trifluoperazine and sertraline
exhibited synergy with fluconazole against each fungal
species, we tested whether other ergosterol biosynthesis
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Figure 5 Rationalization of synergistic interactions by integration of chemical–genetic and genetic interaction networks. (A) Bipartite graph of genetic interactions
between top 50 chemical–genetic interactors of fluconazole and the signature deletion strains sensitive to the five membrane active compounds. As PDR5 was a
member of both sets, it is positioned midway between the two sets. Enriched Gene Ontology (GO) SLIM biological processes are indicated (adjusted P-valueo0.05).
GO enrichment was calculated and visualized using GOlorize (Garcia et al, 2007). (B) Chemical–genetic space (CGS) simulation with the 50 most sensitive deletion
strains for each of the synergistic drugs as well as the signature deletion strain set. Arrows indicate the number of actual genetic interactions for the different drugs; black
curve represents the background distribution of genetic interactions between two random sample sets of 50 non-essential deletion strains chosen from 1143 strains that
respond to a variety of different chemicals and drugs (Hillenmeyer et al, 2008); dark red curve depicts the same background distribution except that the second sample
set size was chosen to match the size of signature deletion set. Asterisks indicate a P-value o0.05. (C) Drug sensitivity of 11 of the 14 signature deletion strains
identified in this study for 16 previously profiled psychiatric drugs present in the Prestwick library (Ericson et al, 2008). Strong activity refers to compounds that were hits in
the primary screens, that is, at least 2 MAD away from the diagonal, whereas weak activity refers to compounds that showed at least 20% growth inhibition and were41
MAD away from the diagonal. Source data is available for this figure at www.nature.com/msb.
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inhibitors might exhibit synergy with these compounds.
We assessed interactions with ketoconazole, an imidazole
inhibitor of ERG11, and terbinafine, an inhibitor of the Erg1
squalene epoxidase in Cryptococcus, Candida and Saccharo-
myces. Ketoconazole was synergistic with both psychiatric
drugs in all fungal species, whereas terbinafine showed
synergies with sertraline in Candida and Saccharomyces but
not in Cryptococcus, and synergized with trifluoperazine
only in Saccharomyces (Table IA). These findings suggest that
while mechanisms of synergy are conserved between different
inhibitors of the same enzymes/pathways, species-specific
differences readily emerge with different compounds, likely
due to subtle differences in genetic network structure (Kuo
et al, 2010).
Higher order combinations of synergizers
Compounds that act in an identical manner are in principle
expected not to exhibit synergy but instead should show only
additive dosage effects. We examined pairwise combinations
within four members of the membrane active group (sertra-
line, trifluoperazine, suloctidil and tamoxifen), as well as with
the sphingolipid-selective synergizer L-cycloserine (Table IB).
Despite their partially overlapping genetic profiles, synergistic
interactions in S. cerevisiae were observed between tamoxifen
and trifluoperazine (FICI¼0.5), sertraline and trifluoperazine
(FICI¼0.4) and sertraline and tamoxifen (FICI¼0.5). These
synergies suggested that in addition to the core effects on
membrane permeability, each compound likely elicits one or
more specific effects that contribute to overall mechanism
of action, and that combining these effects results in further
synergism. This observation predicted that higher order
combinations between synergizers might lead to even stronger
growth inhibition. When compound pairs were tested in the
presence of fluconazole in three-way combinations, fungal
growth was often potently inhibited (Table IB). Titration of
fluconazole concentrations revealed exquisite sensitivity
to the suloctidil/trifluoperazine, L-cycloserine/suloctidil and
L-cycloserine/tamoxifen combinations in the presence of just
1/8 MIC fluconazole (Table IB). The L-cycloserine/suloctidil
pair exhibited the most potent synergy with fluconazole
with an FICI of 0.31. These results demonstrate that it is
possible to incrementally build higher order synergistic
combinations based on the subtly different properties of
individual synergizers, even within in the same class.
In vivo synergy in an insect model of infection
The caterpillar of the greater wax moth Galleria mellonella is a
validated in vivo infection model for study of Cryptococcal
virulence, host immune responses to infection and the effects of
antifungal compounds (Mylonakis et al, 2005; Scully and
Bidochka, 2006; Cowen et al, 2009). We assessed the effect of a
synergistic drug combination on the survival rate ofG.mellonella
infected with C. neoformans because of the prevalence of this
virulent pathogen in immune-suppressed individuals. G. mello-
nella was inoculated with C. neoformans H99 and subsequently
treated with fluconazole and sertraline, individually and in
combination. The synergistic action of fluconazole and sertraline
was evident in G. mellonella survival rates when compared with
either drug alone (Figure 6A and B). Survival increased by 40%
when treated with fluconazole and sertraline in combination,
with an overall 60% survival rate after seven days of infection
(Po0.02 for fluconazole versus fluconazole/sertraline). These
results demonstrate that potentiators of fluconazole activity
identified in vitro exhibit comparable activity in an animal model
of infection.
Synergistic activity against fluconazole-resistant
Candida isolates
To address whether syncretic compounds can act on clinically
resistant strains, we investigated whether the combination of
fluconazole and sertraline is effective against fluconazole-
resistant clinical isolates of C. albicans (F-07-2007, F-01-2008),
C. glabrata and a resistant control strain C. parapsilosis (ATCC
22019). Sertraline increased the susceptibility of resistant
strains to fluconazole by up to 32-fold (Figure 6C and D;
Supplementary Table S7). In the presence of sertraline, flucona-
zole MIC values ranged from 2 to 8mg/ml, comparable to
wild-type (Caf2-1, MIC¼8mg/ml) and drug pump-deficient
Table I Combinations of syncretic drugs exhibit species-specific synergism and higher order interactions with fluconazole
Terbinafine Terbinafine Ketoconazole Ketoconazole
Trifluoperazine Sertraline Trifluoperazine Sertraline
(A) FICI values for drug combinations in different fungal species
C. neoformans (H99) 2 0.75 0.25 0.38
C. albicans (Caf2-1) 2 0.5 0.38 0.16
S. cerevisiae (BY4741) 0.38 0.52 0.38 0.31
Sert (32) Sert (64) Tri Tri+FLC (4) Tam Tam+FLC (4) Suloc Suloc+FLC (4)
(B) FICI values for double and triple drug combinations in S. cerevisiae
Trifluoperazine 0.38 0.50
Tamoxifen 0.50 0.63 0.50 0.75
Suloctidil 1.25 1.50 2.00 0.56 1.00 0.75
L-Cycloserine 1.25 0.63 1.00 2.00 1.00 0.52 2.00 0.31
(A) FICIs from combinationmatrix analysis of sertraline, trifluoperazine, with the ergosterol inhibitors terbinafine and ketoconazole in different species. (B) FICIs from
combination matrix analysis of syncretic drugs and higher order combinations. Trifluoperazine (Tri), tamoxifen (Tam), suloctidil (Suloc) and L-cycloserine were
combined as indicated, in the presence or absence of 1/8 MIC fluconazole (4 mg/ml) and assayed for growth inhibition of a S. cerevisiae strain (BY4741). FICI values
o0.5 indicate synergy, values between 0.5 and 1 indicate additivity and values41 indicate no interaction. Drug concentrations are given in mg/ml.
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(MIC¼2mg/ml) strains of C. albicans. The sertraline/fluconazole
combination was synergistic in both C. albicans clinical isolates
as well as the C. parapsilosis reference strain, but not in the
C. glabrata strain. As noted above, this differential sensitivity
may indicate strain-specific drug effects, or differentmechanisms
of drug resistance (Kuo et al, 2010). We conclude that syncretic
activities in reference laboratory strains can be transposed to
drug-resistant pathogens derived from clinical environments.
Discussion
Systematic screens for syncretic combinations
reveal new antifungal chemical space
The combination of known antifungal agents is an established
therapeutic tactic in infectious disease control (Johnson and
Perfect, 2010). Here, we show that antifungal chemical space
can be systematically expanded through the combination of
a known antifungal drug with other bioactive compounds
that do not have antifungal activity per se, including off-patent
drugs previously approved for other indications. Novel
syncretic drug combinations were readily identified in
systematic screens against different fungal pathogens in the
presence of subtherapeutic concentrations of fluconazole.
These chemically diverse drug hits derive from a broad
spectrum of human therapeutic areas that otherwise would
not have been explored by infectious disease clinicians.
Although hits from screens for fluconazole potentiation in
the S. cerevisiaemodel system can be transposed to pathogenic
fungi (Borisy et al, 2003; Zhang et al, 2007; Jansen et al, 2009;
Epp et al, 2010), our primary screen data reveals considerable
species specificity that by definition cannot be predicted from
model organism drug-gene interactions. Indeed, in our
primary screen, while 58% (25/43) of hits against S. cerevisiae
exhibited synergistic activity against one or more fungal
pathogens, only 19% (25/130) of the total hits against
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Figure 6 Synergistic activity of sertraline and fluconazole in an in vivo infection model and against clinical isolates. (A) G. mellonella caterpillars were injected with
8 103 cfu C. neoformans H99 on day 0 and drugs alone or in combination (1 mg fluconazole; 26 mg sertraline) on the first day and incubated for 1 week at 371C. Values
are mean of three independent experiments; error bars indicate standard deviation of the mean. (B) Uninfected G. mellonella caterpillars (top); melanization of infected
G. mellonella caterpillars without drug treatment (bottom). (C) Combination matrix assays against drug-resistant Candida strains. Residual growth was plotted as a
function of combinations of two-fold dilutions of each drug. (D) Bliss synergy analysis for combination assays shown in panel (C). The apparent absence of synergy at
the highest fluconazole concentrations for C. albicans and C. parapsilosis is due to growth inhibition caused by fluconazole alone. Drug concentrations are in mg/ml.
Source data is available for this figure at www.nature.com/msb.
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pathogenic species were detected in S. cerevisiae. This
observation underscores the need to undertake primary
screens in the pathogen of interest.
Many syncretic combinations exhibited fungicidal activity, a
highly desirable feature for neutropenic or otherwise immune-
compromised patients. The fungicidal combination of fluco-
nazole and the antidepressant sertraline (Zolofts) was
effective against all species tested, including drug-resistant
clinical isolates of Candida, and in an in vivo insect model of
C. neoformans infection. Therapeutic intervention for fungal
infections of the CNS is a particular clinical challenge because
of the stringent requirement to breach the blood brain barrier.
The fact that sertraline targets serotonin receptors in the CNS
suggests that the sertraline-fluconazole combination may be
effective in the treatment of fungal meningitis.
Molecular mechanisms and prediction of drug
synergism
Genome-wide chemical–genetic profiles of a selected set of
six fungicidal synergizers revealed two different patterns of
synergy. Five compounds—trifluoperazine, tamoxifen, clomi-
phene, sertraline and suloctidil—elicited genetic sensitivities and
cell biological phenotypes associated with a loss of membrane
integrity. The membrane perturbation caused by these com-
poundsmay increase susceptibility to accumulation of ergosterol
pathway intermediates, impair fluconazole export by drug efflux
pumps and/or impair import of exogenous ergosterol (Kuo et al,
2010). It is also possible that the synergizers affect active import
of azoles through altered localization of drug transporters or
general membrane perturbation (Mansfield et al, 2010). Notably,
all five membrane active compounds are cationic amphiphilic
drugs (CADs) that intercalate preferentially into one side of the
lipid bilayer, thereby causing membrane expansion and cell wall
stress (Sheetz and Singer, 1974), consistent with the observed
chemical–genetic interactions withNEO1,DRS2, SLT2 and BCK1.
Moreover, genetic resistance to CADs is conferred by perturba-
tion of vesicularmembrane biogenesis and/or trafficking (Rainey
et al, 2010). The synthetic lethal genetic interactions that occur
between strains in the fluconazole and membrane active
chemical–genetic profiles retrospectively predicted the synergis-
tic effects of other hits in our primary screens. Moreover, when
combined with another source of chemical–genetic interaction
data (Ericson et al, 2008), the membrane active signature strain
set correctly identified further synergistic hits in our primary
screen data. In addition, the genetic interaction profile of
L-cycloserine correctly predicted a novel synergistic interaction
between the sphingolipid biosynthesis inhibitor myriocin and
fluconazole. The potentiation of fluconazole activity by CADs
and/or inhibition of sphingolipid biosynthesis may allow new
general approaches to antifungal therapy in the clinic. As genetic
and chemical–genetic space is elaborated, mechanism-based
predictive approaches should become a powerful means of
identifying new synergistic combinations.
Species-specific syncretic effects
We observed many genus- and species-specific syncretic
interactions, which reflects differences in the genetic networks
that dictate cellular responses to each compound (Perlstein
et al, 2007). Since divergence from a common ancestor over
100 million years ago, different pathogenic species have
adapted to particular host environments. For example, genetic
plasticity of the fungal mating-type locus affects survival in
mammalian hosts (Nielsen and Heitman, 2007). Develop-
mental system drift (True and Haag, 2001) can also affect drug
susceptibility, as shown by the differential effects of nikkomy-
cin Z on chitin synthase paralogs in Saccharomyces and
Candida (Gaughran et al, 1994; Sudoh et al, 2000). Marked
differences in the transcriptional response of Saccharomyces,
Candida and Kluyveromyces to fluconazole treatment under-
score the quite distinct mechanisms whereby different species
can respond to the same drug (Kuo et al, 2010). More generally,
species differences in the response to chemical perturbation
may reflect the evolutionary plasticity of genetic interaction
networks (Kapitzky et al, 2010). Species-selective antifungal
combinationsmay afford ameans to both increase efficacy and
decrease host toxicity. Systematic analysis of drug–drug
interactions may also provide a means to classify and predict
drug mechanism of action (Yeh et al, 2006; Hopkins, 2008).
Higher order drug–drug interactions
The densely connected structure of genetic networks predicts
that it should be possible to devise higher order drug
combinations with greater selectivity and potency (Sharom
et al, 2004; Agoston et al, 2005; Lehar et al, 2007). That is,
compounds that target multiple genetically redundant parallel
pathways may exhibit n-way synergies. In an initial elabora-
tion of this concept, we found that the combination of a non-
synergistic pair (suloctidil and L-cycloserine, drawn from the
membrane active and sphingolipid target classes, respectively)
with a low dose of fluconazole resulted in a highly potent
three-way synergism. Somewhat unexpectedly given their
shared core genetic profiles, pairwise tests of four compounds
in the membrane active class also revealed synergistic
interactions in the absence of fluconazole. This type of drug–
drug interaction, which has been observed previously with
bacteria and yeast (Yeh et al, 2006; Jansen et al, 2009),
suggests that, aside from the common core profile, each drug
must have additional specific targets that contribute to overall
synergism. The complex genetic profiles of each drug reflect
effects on primary and secondary targets in the cell, drug
metabolism and detoxification, and genetic feedback between
different network elements (Sharom et al, 2004; Kitano, 2007;
Lehar et al, 2008). Other documented interactions between
fluconazole, reactive oxygen species, Hsp90, calcium metabo-
lism and vesicle trafficking may contribute to these complex
interactions (Cowen et al, 2009; Xu et al, 2009; Epp et al,
2010; Gamarra et al, 2010). We note that although shared drug
profiles have been suggested to be predictive of synergistic
interactions (Jansen et al, 2009), in many instances this is not
the case (Yeh et al, 2006). Even drugs with well-documented
mechanisms of action can have substantially different genetic
interaction profiles compared with their presumptive targets.
For example, although the genetic interaction profiles of
fluconazole and its known target ERG11 exhibit significant
overlap, more than half of the interactions are not shared
(Parsons et al, 2004). Recently, it has been shown that drug
combinations can exhibit remarkably selective but unpredict-
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able effects on the abundance of many different proteins
(Geva-Zatorsky et al, 2010).
Therapeutic implications
The benefits of combinatorial anti-infective therapies include
a decrease in the rate of selection of resistant strains, a lower
required dosage of individual drugs, a decrease in host
toxicity and enhanced antimicrobial activity (Sharom et al,
2004; Hopkins, 2008; Lehar et al, 2008). As shown in this study
and elsewhere (Zhang et al, 2007; Jansen et al, 2009; Epp et al,
2010), syncretic combinations of drugs with improved
antifungal properties can be readily identified in both
model fungal species and highly pathogenic clinical isolates.
Importantly, while it is a potential concern that undesirable
side effects may arise from drug combinations, as occurs for
example with known contraindicated drugs, it has recently
been shown that synergistic combinations usually yield
enhanced selectivity without adverse side effects (Lehar
et al, 2009). As noted above, these benefits may include
improved activity in therapeutically recalcitrant tissues,
such as the CNS. These combinatorial principles apply equally
to viral and bacterial pathogens, cancer and other genetic
diseases (Borisy et al, 2003; Fitzgerald et al, 2006; Hopkins,
2008; Lehar et al, 2009).
Materials and methods
Chemicals, high-throughput screens and MIC
determination
Fluconazole was purchased from Sandoz (Quebec, Canada). All other
compounds were obtained from Sigma (St Louis) or Prestwick
Chemicals (Illkirch, France). The Prestwick Chemical library was
screened in duplicate in the presence and absence of 1/2 MIC
fluconazole at a final concentration of 30mM in 384-well flat bottom
microtitre plates. OD600 was determined after 48 h at 30 or 371C. MIC
determinations were based on Clinical and Laboratory Standards
Institute (CLSI) protocols (Eliopoulos and Moellering, 1991; Odds,
2003), with the exception that yeast SC medium was used instead of
mammalian cell RPMI 1640 medium. Overnight cultures in synthetic
complete media (SC: 0.67% Difcot yeast nitrogen base w/o amino
acids, 0.08% amino acid add back and 2% glucose) were diluted in
0.85% NaCl to an OD530 of 0.11, followed by a 1:100 dilution in 0.85%
NaCl, and a final 1:20 dilution in SC media. Two-fold dilution series
(0–128mg/ml) of fluconazole and other antifungal drugswere added to
200 ml of diluted culture in 96-well plates and OD600 determined after
48 h at 30 or 371C. For fluconazole, MIC was set at the lowest
concentration that caused 80% reduction in growth, corresponding to
two on the azole MIC numerical scale. For other drugs, MIC was set as
the lowest concentration that yielded no growth.
Time kill MIC assays were performed at six different concentrations
of compound and fluconazole (fluconazole at MIC, fluconazole at 1/4
MIC, compound at MIC, compound at 1/4 MIC, both fluconazole and
compound at MIC, and both fluconazole and compound at 1/4 MIC).
At 0, 24 and 48 h dilutions from each well were spotted on an SC agar
plate, incubated for 48 h and colony counts determined. A fungicidal
effect was defined as43log10 (99.9% killing) reduction in CFU/ml at
synergistic concentrations after 24 h incubation.
Synergy matrix assays
Fluconazole and syncretic compounds were two-fold serially diluted
across the rows and columns of a 96-well plate (0–128 mg/ml; for
daunorubicin HCl, terbinafine, trifluoroperazine dihydrochloride and
ellipticine dilutions were from 0–64mg/ml), incubated with fungal
cultures and OD600 determined after 48 h. The FIC index of each drug
combination was determined by adding the individual FIC values, as
calculated by standard CLSI protocols (Eliopoulos and Moellering,
1991; Odds, 2003). To probe chemical interactions between sertraline,
trifluoperazine, L-cycloserine, suloctidil and tamoxifen, checkerboard
assays were carried out between these five compounds in the absence
and presence of 1/2 and 1/8 MIC fluconazole (16 and 4mg/ml,
respectively).
Chemical–genetic profiles and secondary assays
S. cerevisiae deletion collections (MATa haploid and heterozygous
essential deletion strains) were obtained from Research Genetics
(Germany). Compounds were screened at a concentration that caused
B30% growth inhibition at a final DMSO concentration of 0.2%
(Giaever et al, 1999). Deletion pools were grown for 10 generations,
gDNA extracted and barcode tags amplified with fluorescently labeled
UP and DN primers, followed by hybridization of PCR products to
spotted barcode microarrays (Cook et al, 2008). Arrays were scanned
on a GenePix 4200AL and analyzed with GenePix Pro 6.0 software.
Data sets are available at ArrayExpress (E-MTAB-394). Chemical–ge-
netic interactions were confirmed in quantitative growth assays at
301Cwith continuous shaking at 564 r.p.m. on a Sunrise shaker/reader
(Tecan); OD600 readings were taken every 15min and values at the end
of logarithmic phase used to calculate the log ratio between deletion
andwild-type strains. For sorbitol rescue, wild-type strainswere grown
in the presence of indicated compounds and 1M sorbitol. For
microscopy, cells were embedded in 1% low melt agarose and stained
with CalcofluorWhiteM2R (Sigma),Mitotracker Green FM (Molecular
Probes) or FM4-64 (Molecular Probes) and imaged at  100 on a Leica
DMI 6000 B microscope with a Hamamatsu Orca ER-AG camera and
Volocity 4 software. Images were deconvolved using AutoDeblur Gold
CWF using 2-D blind deconvolution and 10 iterations per image.
Computational analysis of gene-drug network
interactions
The 50most sensitive deletion strains fromduplicate chemical–genetic
profiles for clomiphene, L-cycloserine, sertraline, suloctidil, tamoxifen
and trifluoperazine were tested against the top 50 fluconazole-
sensitive deletion strains (from replicate arrays at 8 mM). Shared
genetic interactions between the sets of deletion strains were
determined based on genetic interaction data obtained from
BioGRID (Breitkreutz et al, 2008; BIOGRID release 2.62, http://www.
thebiogrid.org). Visualization of bipartite graphs and simulations was
performed with an online tool available at http://tyerslab.bio.ed.
ac.uk/tools/genelookup_bipartite.php. Simulations based on CGS
were derived from 1143 non-essential deletion strains that respond
to various drug treatments (Hillenmeyer et al, 2008). For each drug
pair, control gene sets of the same size were picked at random and the
number of genetic interactions counted to generate a background
distribution of the number of interactions that would occur by chance,
based on the compiled genetic interaction data. This distribution was
used to calculate the P-value for each drug pair. For PPP, the chemical–
genetic interactors of fluconazole and each of the synergistic drugs
were pooled, randomly assigned to two groups and genetic interac-
tions counted to obtain a background distribution for each drug pair.
The definition of the signature deletion strain set was based on
confirmatory quantitative growth curve assays (Figure 3D). For both
the CGS and PPPmethods, 10 000 simulations were conducted for each
drug pair. To predict potential synergistic candidates based on overlap
with published chemical–genetic profiles (Ericson et al, 2008), we
used a binary data matrix based on a Z-score cutoff of ±3. The
significance of enrichment was calculated based on the number of
genes that overlapped with the signature strain set; a subset of 4 out of
11 genes was significant with a P-valueo0.05.
Insect larvae assays
Ten weight matched (250–400mg/worm) G. mellonella caterpillars
per dish were inoculated with C. neoformans H99 and subsequently
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injectedwith different combinations of compound, fluconazole and/or
control solutions (Mylonakis et al, 2005). Over a 7-day period,
caterpillars were examined visually for discoloration due to melaniza-
tion and for failure to respond to touch as an inviability end point.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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